symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NUVL,53.16,1.352166,545885,3031438315,0,18.19-65.5,-4.8,"Nuvalent, Inc.",USD,0001861560,US6707031075,670703107,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.nuvalent.com,"Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.",Dr. James R. Porter Ph.D.,Healthcare,US,78,857 357 7000,One Broadway,Cambridge,MA,02142,,0,https://financialmodelingprep.com/image-stock/NUVL.png,2021-07-29,False,False,True,False,False
